Skip to main content

Table 1 Correlation between clinicopathological features and PD-1, PD-L1, and PD-L2 expression in 177 all breast cancers

From: Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Parameters PD-1 p value PD-L1 p value PD-L2 p value
Positive (n = 37) Negative (n = 140) Positive (n = 42) Negative (n = 135) Positive (n = 53) Negative (n = 124)
Intrinsic subtype
 TNBC 18 (48.6%) 43 (30.7%) 0.041 24 (57.1%) 37 (27.4%) < 0.001 20 (37.7%) 41 (33.1%) 0.549
 Non-TNBC 19 (51.4%) 97 (69.3%) 18 (42.9%) 98 (72.6%) 33 (62.3%) 83 (66.9%)
Intrinsic subtype
 HER2+BC 3 (81.1%) 42 (30.0%) 0.004 4 (9.5%) 41 (30.4%) 0.004 16 (30.2%) 29 (23.4%) 0.341
 Non-HER2+ BC 34 (18.9%) 98 (70.0%) 38 (90.5%) 94 (69.6%) 37 (69.8%) 95 (76.6%)
Age at operation
 ≤ 56 15 (40.5%) 72 (51.4%) 0.239 20 (47.6%) 67 (49.6%) 0.820 28 (52.8%) 59 (47.6%) 0.522
 > 56 22 (59.5%) 68 (48.6%) 22 (52.4%) 68 (50.4%) 25 (47.2%) 65 (52.4%)
Menopause
 Negative 14 (37.8%) 58 (41.4%) 0.693 18 (42.9%) 54 (40.0%) 0.742 23 (43.4%) 49 (39.5%) 0.630
 Positive 23 (62.2%) 82 (58.6%) 24 (57.1%) 81 (60.0%) 30 (56.6%) 75 (60.5%)
Tumor size (cm)
 ≤ 2 5 (13.5%) 19 (13.6%) 0.993 6 (14.3%) 18 (13.3%) 0.875 9 (17.0%) 15 (12.1%) 0.385
 > 2 32 (86.5%) 121 (86.4%) 36 (85.7%) 117 (86.7%) 44 (83.0%) 109 (87.9%)
Lymph node status
 Negative 7 (18.9%) 34 (24.3%) 0.491 10 (23.8%) 31 (23.0%) 0.910 12 (22.6%) 29 (23.4%) 0.914
 Positive 30 (81.1%) 106 (75.7%) 32 (76.2%) 104 (77.0%) 41 (77.4%) 95 (76.6%)
Nuclear grade
 1, 2 26 (70.3%) 111 (79.3%) 0.244 31 (73.8%) 106 (78.5%) 0.524 39 (73.6%) 98 (79.0%) 0.427
 3 11 (29.7%) 29 (20.7%) 11 (26.2%) 29 (21.5%) 14 (26.4%) 26 (21.0%)
Ki67
 ≤ 14% 13 (35.1%) 61 (43.6%) 0.355 16 (38.1%) 58 (43.0%) 0.576 18 (34.0%) 56 (45.2%) 0.167
 > 14% 24 (64.9%) 79 (56.4%) 26 (61.9%) 77 (57.0%) 35 (66.0%) 68 (54.8%)
Pathological response
 pCR 9 (24.3%) 58 (41.4%) 0.056 6 (14.3%) 61 (45.2%) < 0.001 24 (45.3%) 43 (34.7%) 0.183
 Non-pCR 28 (75.7%) 82 (58.6%) 36 (85.7%) 74 (54.8%) 29 (54.7%) 81 (65.3%)
PD-1
 Negative Not determined Not determined   13 (31.0%) 127 (94.1%) < 0.001 31 (58.5%) 109 (87.9%) < 0.001
 Positive 29 (69.0%) 8 (5.9%) 22 (41.5%) 15 (12.1%)
PD-L1
 Negative 8 (21.6%) 127 (90.7%) < 0.001 Not determined Not determined   25 (47.2%) 110 (88.7%) < 0.001
 Positive 29 (78.4%) 13 (9.3%) 28 (52.8%) 14 (11.3%)
PD-L2
 Negative 15 (40.5%) 109 (77.9%) < 0.001 14 (33.3%) 110 (81.5%) < 0.001 Not determined Not determined  
 Positive 22 (59.5%) 31 (22.1%) 28 (66.7%) 25 (18.5%)
  1. TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand